Dr. Soliman Abdul Kader Fakeeh Hospital Co. (4017.SR) — Financial statements
Income statement, balance sheet, and cash flow for Dr. Soliman Abdul Kader Fakeeh Hospital Co. — annual and quarterly history with growth and margin analysis.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3,090↑10.7% | 2,791↑20.0% | 2,327↑15.6% | 2,012↑2.4% | 1,965 | |
| Cost of Revenue | 2,386↑14.1% | 2,092↑22.3% | 1,710↑21.1% | 1,412↑6.4% | 1,327 | |
| Gross Profit | 704↑0.7% | 699↑13.4% | 617↑2.7% | 600↓5.9% | 638 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00↓100.0% | 279↑14.5% | 243↑683.0% | 31↑15.3% | 27 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 59↑20.1% | 49↑758.7% | 6↓50.8% | 12 | |
| SG&A Expenses | 405↑19.8% | 338↑15.5% | 292↑47.6% | 198↓14.2% | 231 | |
| Other Expenses | 6↑162.0% | 2↑123.4% | -10↓99.8% | -5↓116.1% | 31 | |
| Operating Expenses | 411↑20.8% | 340↑20.3% | 283↑46.3% | 193↓26.1% | 261 | |
| Total Costs & Expenses | 2,797↑15.0% | 2,432↑22.0% | 1,993↑24.1% | 1,605↑1.1% | 1,588 | |
| Operating Results | ||||||
| Operating Income | 293↓18.4% | 359↑7.5% | 334↓18.0% | 407↑8.1% | 376 | |
| Depreciation & Amortization | 0.00↓100.0% | 163↑9.0% | 149↑115.8% | 69↑13.8% | 61 | |
| EBITDA | 293↓46.3% | 546↑3.7% | 526↑16.6% | 451↑3.2% | 437 | |
| EBIT | 293↓23.4% | 383↑1.6% | 377↓1.4% | 382↑1.5% | 376 | |
| Interest & Other Income | ||||||
| Net Interest Income | -28↑61.8% | -72↑9.2% | -79↓155.2% | -31↓8.5% | -29 | |
| Interest Income | 21↓10.0% | 24↓44.8% | 43 | 0.00 | 0.00 | |
| Interest Expense | 49↓49.0% | 96↓21.7% | 122↑293.3% | 31↑8.5% | 29 | |
| Non-Operating Income | 0.00↑100.0% | -24↑44.8% | -43↓271.5% | 25 | 0.00 | |
| Other Income / Expenses | -13↑82.5% | -72↑9.2% | -79↓41.7% | -56↓405.2% | -11 | |
| Income Before Tax | 281↓2.3% | 287↑12.7% | 255↓27.5% | 351↓3.9% | 365 | |
| Income Tax Expense | 32↑38.0% | 23↑3.1% | 23↑11.0% | 20↑347.9% | 5 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 248↓5.9% | 264↑13.6% | 232↓29.8% | 331↓8.3% | 361 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 290↑0.9% | 288↑2.8% | 280↓14.3% | 326↓2.4% | 334 | |
| Bottom-Line Net Income | 290↑0.9% | 288↑2.8% | 280↓14.3% | 326↓2.4% | 334 | |
| EPS (Basic) | 1.26↓4.5% | 1.32↑8.2% | 1.22↓25.2% | 1.63↓51.2% | 3.34 | |
| EPS (Diluted) | 1.26↓4.5% | 1.32↑8.2% | 1.22↓25.2% | 1.63↓51.2% | 3.34 | |
| Weighted Average Shares | 230↑5.9% | 217↓5.6% | 230↑15.0% | 200↑100.0% | 100 | |
| Weighted Average Diluted Shares | 230↑5.9% | 217↓5.6% | 230↑15.0% | 200↑100.0% | 100 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.